Long-Acting Antiretrovirals for HIV

Similar documents
Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York

CROI 2017 Highlights What s New in Antiretrovirals (Part 2)

Long Acting ART for Treatment and PrEP

Oral Versus Injectable Delivery, Impact on Adherence/Tolerability

Didactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016

Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016

Investigational Approaches to Antiretroviral Therapy

Investigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents

Future Perspectives for Delivery of Antiretroviral Drugs

Criteria for Oral PrEP

Investigational Approaches to Antiretroviral Therapy

ARVs in Development: Where do they fit?

Long-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018

WHEN TO START? CROI 2015: Focus on ART

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

Disclosures (last 12 months)

The injectables: a new silver bullet?

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City

ART and Prevention: What do we know?

What s in the Biomedical Prevention Pipeline

Update on Biomedical Prevention. Thomas C. Quinn, MD, MSc

PrEP: Is Longer Better? Myron S. Cohen, MD

Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC

23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service,

New options for new and old patients. Antonella Castagna

4/14/2016. Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections

CROI 2013: New Drugs for Treatment and PrEP

New Drugs in Development Are We Ready for Long-Acting ART?

The pipeline: Long-acting agents and new drugs. Charles Flexner, MD Johns Hopkins University

Next Generation PrEP? Injectable & Implantable ARVs

v Dr Anton Pozniak Chelsea and Westminster Hospital, London Injectable ARVs a S.W.O.T Analysis

11/7/2016. Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama

Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors

DRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015

Pharmacology Lessons from Chemoprophylaxis Studies. Marta Boffito, MD, PhD St Stephen s AIDS Trust Chelsea and Westminister Hospital London, UK

Novel HIV Prevention Methods for Women

Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches

REGULATORY PATHWAYS AND CLINICAL TRIAL DESIGN FOR LONG-ACTING PrEP

Are the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine

PrEP adherence in Black MSM in HPTN 073 and Beyond

The next generation of ART regimens

Long Acting HIV Drugs for Prevention: what are the data? Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint

Injectable Antiretrovirals The Promise and the Peril. Ian McGowan MD PhD FRCP University of Pittsburgh, PA, USA Cape Town, 6 th October, 2015

HIV IS NOT OVER. Update From the Conference on Retroviruses and Opportunistic Infections (CROI) Learning Objectives

Simplifying HIV Treatment Now and in the Future

Biomedical Prevention Update Thomas C. Quinn, M.D.

Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results

Update on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School

New Delivery Systems and Long Acting Antiretroviral Drugs

The role of Integrase Inhibitors during HIV prevention

10/05/2016. Long-Acting Antiretroviral Agents For Prevention. Dr Paul Benn MB ChB FRCP

What is the Virologic Support for Two-Drug Regimens?

Reduced Drug Regimens

Prevenção do HIV e o papel dos inibidores da integrasse

The Prevention Landscape for Women: Yesterday, Today and Tomorrow. Nyaradzo M. Mgodi (MBChB, MMed) MTN Regional Meeting September 25, 2018

HIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko

CROI 2017 Review: Novel ART Strategies

Taking a shot at HIV with longacting injectable ARVs for treatment and prevention

Antiretroviral Treatment Strategies: Clinical Case Presentation

Long-acting Treatment with Antiretrovirals

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018

CROI 2016: Top Ten for Clinicians

CROI 2018 Update. Christian B. Ramers, MD, MPH, AAHIVS. Assistant Medical Director - Research/Special Populations Family Health Centers of San Diego

11/8/2016. Moving Beyond Truvada: The (Current) Future Pipeline for PrEP. Prevention Modalities

PRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March

REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE

Didactic Series. CROI 2014 Update. March 27, 2014

Roger Shapiro, MD, MPH Harvard TH Chan School of Public Health Botswana-Harvard Partnership May 2018

Nanoformulations: Update from ViiV Healthcare. Cabotegravir: Long Acting HIV Integrase inhibitor

Antiretroviral Therapy Where we are and where we are going

Antiretroviral Treatment: What's in the Pipeline

Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?

What are the most promising opportunities for dose optimisation?

Antiretrovirals for HIV Prevention: Optimizing the Use of PrEP and PEP in 2018

Treating HIV in 2018 Interactive Cases From the Clinic(ians)

Second and third line paediatric ART strategies

Actualización y Futuro en VIH

hiv treatmen + bulletin (e) july-august 2017 htb(e): volume 18 number 7/8 Published by HIV i-base C O N T E N T S

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN

Long-Acting Antibodies and Drugs as HIV Prevention Agents. David D. Ho, M.D.

Switching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn

Fertility Desires/Management of Serodiscordant HIV + Couples

A Quarterly Update on HIV Prevention Research. Vol. 8 No. 2

Mucosal Assays in Oral and Long Acting (LA) Antiretroviral PrEP Trials. Ian McGowan MD PhD FRCP University of Pittsburgh Pittsburgh, PA USA

Antiretroviral Therapy in 2016

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo

Pre-exposure Prophylaxis (PrEP)

VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects

Pharmacokinetic and pharmacodynamic profile of maraviroc in rhesus macaques after a single oral dose

PrEP Dosing Strategies

Two Drug Regimens Pros and Cons. Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany

The Antiretroviral Pipeline

Injectable Pre-exposure Prophylaxis

Management of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine

PrEP: Pre Exposure Prophylaxis

hiv treatmen + bulletin (e) march-april 2016 htb(e): volume 17 number 3/4 Published by HIV i-base C O N T E N T S ISSN

David Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone

Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town

PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients

Clinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia

Transcription:

Long-Acting Antiretrovirals for HIV R.M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Chief, Division of Infectious Diseases Weill Cornell Medicine New York City

Disclosures None

Single Tablet ART Regimens: 2018 TDF/FTC/EFV (2006) TDF/FTC/RPV (2011) TDF/FTC/EVG/cobi (2012) ABC/3TC/DTG (2014) TAF/FTC/EVG/cobi (2015) TAF/FTC/RPV (2016) TAF/FTC/DRV/c (investigational)

Long-Acting: What s the attraction? Infrequent dosing Longer drug half-lives Lower drug doses needed (nanoformulations) Addresses adherence Addresses pill fatigue Possibility of directly observed therapy (DOT) Tissue targeting (lymph node/macrophage uptake) Protection of health privacy Could avoid treatment-related HIV stigma

NanoART Survey - Results HIV+ U.S. pts currently prescribed ART (N=400) 68% men, 53% African American, mean age 47 48% very concerned about side effects 35% concerned about needles Williams, Nanomedicine (London) 2013;8:1807

Long Acting ART in Clinical Development Approved ibalizumab (IBA) Phase 3 cabotegravir (CAB)-LA rilpivirine (RPV)-LA Phase 2 albuvirtide EFdA (MK-8591) PRO 140 broadly-neutralizing monoclonal antibodies VRC01, 3BNC117, 10-1074, PGT121

Ibalizumab (IBA): HIV Entry Inhibitor Slide 7 of 36 Monoclonal antibody; IV, SC Binds to CD4 receptor Dosing every 1-4 weeks Phase 1a Kuritzkes JID 2004;189:286 Phase 1b Jacobson AAC 2009;53:450 Phase 2a Norris IAS 2006 #TuPE0058 Phase 2b Khanlou IDSA 2011 #LB9 Rx-experienced; 3-class resistance; (N=113) baseline susceptibility to IBA not different for those with drug resistance to NRTIs, NNRTIs, PIs, IIs, ENF or MVC Weinheimer IAS 2017 #MOPEB0352

Slide 8 of 36 Ibalizumab (IBA): HIV Entry Inhibitor Phase 3 Study population: VL>1000, on ART >6 months, 3-class resistance, >1 sensitive drug (N=40) Study treatment: continue ART, add IBA 800 mg day 7 +OBR day 14, +IBA day 21 and q 2 wks 24 weeks HIV RNA <50 copies/ml in 43% Lewis CROI 2017 #449LB Lalezari IDWeek 2016 #LB6 27 continued OBR with IBA 48 weeks HIV RNA <50 copies/ml in 59% Emu IDWeek 2017 #1686

Slide 9 of 36 Ibalizumab (IBA): HIV Entry Inhibitor 3/6/2018: FDA approves for heavily rx-experienced adults with MDR HIV-1 infection failing their current antiretroviral regimen Dosing: Loading dose of 2g IV, then 800mg IV q2weeks Cost: US list price: $118,000/year (not including cost of infusions)

Cabotegravir (CAB, GSK 1265744) Integrase inhibitor similar to DTG; similar resistance Potent in HIV+ individuals (5, 10, 30, 60 mg oral) Spreen HIV Clin Trials 2013;14:192 Nanotechology formulation; SC + IM injections T ½ 21-50 days! Supports monthly or quarterly dosing Safety: injection site reactions (ISR; mild) / nodules with SC dosing Spreen JAIDS 2014;67:481

LATTE-2: IM CAB + IM RPV Randomized, open-label, phase 2b, non-inferiority study Study population: ART-naïve (N=309) Study rx: PO CAB + ABC/3TC X 4 wks, then randomized 2:2:1 Results (HIV RNA <50 at 96 wks) IM CAB + IM RPV q8 wks 94% IM CAB + IM RPV q4 wks 87% PO CAB + ABC/3TC 84% Injection site reactions were nearly universal 97%+ were mild or moderate; lasted a median of 3 days 2 pts (<1%) d/c due to ISR Conclusions: IM non-inferior (comparable) to PO; well-tolerated Phase 3 studies FLAIR (switch from ABC/3TC/DTG; CAB + RPV q4 wks) ATLAS (switch; CAB + RPV q4 wks) ATLAS-2M (switch; CAB + RPV q4 vs. 8 wks) Eron IAS 2017 #MOAX0205LB Margolis Lancet 2017;390:1499

Cabotegravir (CAB) Prevention: HPTN 077 Phase 2a randomized, double-blind, pbo-controlled Study pop: low-risk HIV- participants (N=199); median age 31, 66% women, 34% men Study meds: 3:1 to oral CAB X 4 wks then CAB IM 800 mg q12 weeks or 600 mg q8 wks (or PBO) Results: ISR more common with CAB (34%) vs. PBO (2%); 1.5% d/c ed No other differences in safety/tolerability drug troughs lower with CAB 800 q12 wks Conclusion: CAB 4 wk oral 600 mg IM q8wks optimal Landovitz IAS 2017 #TUAC0106LB

HPTN 083: PrEP with TDF/FTC oral vs. CAB IM Study population: Adult MSM and TGW, at high-risk for HIV acquisition (N=4500) High risk any non-condom receptive anal intercourse (RAI) >5 partners stimulant drug use rectal or urethral STI in past 6 months Study regimen: TDF/FTC daily oral vs. CAB q2 month injections double-blind, double-dummy design Design: non-inferiority, efficacy study Primary endpoint: HIV seroconversion Now enrolling! Slide 23 of 36

Albuvirtide (ABT): HIV Fusion Inhibitor 1/2-life = 11-12 d weekly dosing Pilot study: Study pop: ART-naïve, VL 5K-1M, CD4 >350 (N=20) Design: 7 weeks, open-label, randomized Study regimen: ABT (160 or 320 mg/wk) + LPV/r bid 56% Zhang AIDS Res Ther 2016;13:8

Albuvirtide (ABT): HIV Fusion Inhibitor TALENT (Test Albuvirtide in Treatment-Experienced Patients) Phase 3 -- Second-line therapy following VF on a first-line ART regimen (N=389) Study rx; LPV/r bid + [2 NRTI or ABT] Planned Interim analysis; ½ of study participants (n=175) on study X 48 wks: VL <50; 66% (NRTI) vs. 80% (ABT) non-inferiority In 5 pts on ABT with VL >500 no resistance Wu Glasgow 2016 #O335

MK-8591 (EFdA) 4 -ethynyl-2-fluoro-2 -deoxyadenosine; EFdA Non-obligate chain terminator Inhibits RT by preventing translocation (NRTTI) ½ life 150-160 hours(!) Potent antiviral activity (PBMC EC50 = 0.2 nm) with broad coverage (HIV-1, HIV-2, MDR strains) Accumulates in LN, vagina, rectum (animals) Grobler CROI 2017 #435 Low-dose and parenteral formulations

MK-8591 (EFdA) Grobler CROI 2016 #98 Friedman CROI 2016 #437LB Grobler CROI 2017 #435

MK-8591 (EFdA) Phase 1b, single-dose, monotherapy study Study population: ART naïve (N=30) Matthews IAS 2017 #TUPDB0202LB

MK-8591 (EFdA) Double-blind, placebo-controlled, 3-panel trial HIV- participants MK-8591 (or placebo) 5 mg X 6 weeks, 0.75 mg X 4 weeks, 0.25 mg X 4 weeks Results: After 2-3 weeks of dosing, MK-8591-TP levels exceeded 1.0 pmol/million cells (similar to 10 mg weekly dosing) Tissue (vaginal, rectal) and PBMC levels adequate Conclusion: Low daily doses expected to suppress HIV Matthews CROI 2018 #22 Phase 2 study of MK-8591 + 3TC + doravirine (DOR) now enrolling

MK-8591 -- Prevention MK-8591 3.9 mg/kg (vs. placebo) given to male macaques weekly by oral gavage up to 14 weeks (8/group) 6 days after dosing, macaques exposed to intrarectal SHIV (until infection or a total of 12 challenges) Results: All 8 control macques infected; all MK-8591 macaques remain (-) Markowitz IAS 2017 #MOAX0203LB Follow-up study with lower doses MK-8591: 1.3, 0.43, 0.1 mg/kg weekly (8 macaques/group) Results 1.3 mg/kg: all 8 remained uninfected 0.43 mg/kg: all 8 remained uninfected 0.1 mg/kg: 2 of 8 became infected Conclusions: MK-8591 protective at low doses Equivalent to 250 µg/week or 10 µg/day in humans(!) Markowitz CROI 2018 #89LB

PRO 140 Humanized CCR5 monoclonal antibody Administered IV or SC; dosed weekly or every 2 weeks Proof of concept study of PRO 140 given subcutaneously for 15 days in 44 pts with R5 virus (only): Maximum VL (log cps/ml) 162 mg/wk 0.99 324 mg/2 wk 1.37 324 mg/wk 1.65 Jacobson JID 2010;201:1481-7

PRO 140 Phase 2b, open-label single-arm extension study Adult pts with R5 virus on ART with HIV RNA <40 c/ml (N=42) Changed to maintenance with PRO 140 350 mg SC weekly After 13 weeks of virologic suppression, 16 eligible pts started extension with self-administered PRO 140 Results: 10 pts with virologic suppression up to 2 years 5 pts with viral rebound (mean time 329 days) 1 pt moved Conclusion: potential for LA maintenance rx Lalezari CROI 2017 #437

HIV-1 Broadly Neutralizing Antibodies Klein, Science 2013;341:1199

Potential Uses of Broadly Neutralizing HIV Antibodies D HIV Prevention Klein, Science 2013;341:1199

Long-Acting Implants Potential advantages over injectables Removable More consistent and predictable drug release PK not dependent on injection site May remain in place for years (inert, nondegradable subcutaneous versions) Potential disadvantages over injectables Specialized device required for insertion Minor surgical procedure to remove Regulated as both a drug and a device Difficulty moving to a generic marketplace

Long-Acting Subdermal Implants: Tenofovir Alafenamide (TAF) in Dogs Gunawardana AAC 2015;59:3913

Long-Acting ART: Issues Injection volumes Oral lead-in Adverse events and side effects Coverage of the long drug concentration tail Pharmacokinetic variability Dosing strategies for: children adolescents pregnant women

Long-Acting ART: Conclusions Despite ART one-pill, once-daily regimens there is interest in long-acting ART for HIV treatment and prevention Oral weekly or biweekly Injectable every 2, 4, 8, 12 weeks (or longer) There are approved (ibalizumab) and investigational agents in advanced (cabotegravir LA, rilpivirine LA) and earlier (albuvirtide, MK- 8591, PRO 140, BNAbs) clinical development. There are potential benefits as well as potential issues with long-acting ART. Further research is required.

Acknowledgments Cornell HIV Clinical Trials Unit (CCTU) Division of Infectious Diseases Weill Cornell Medicine AIDS Clinical Trials Group (ACTG) HIV Prevention Trials Network (HPTN) Division of AIDS, NIAID, NIH The patient volunteers! Charles Flexner for slides